Trial Profile
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms TRICC-C
- 19 Jan 2019 Primary endpoint has not been met. (progression free survival), as per Results presented at the 2019 Gastrointestinal Cancers Symposium
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
- 01 Jun 2012 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013, based on an abstract presented at ASCO 2012.